Safi U Khan, Swapna Talluri, Haris Riaz, Hammad Rahman, Fahad Nasir, Irbaz Bin Riaz, Sudhakar Sattur, Haitham Ahmed, Edo Kaluski, Richard Krasuski
Background The comparative effects of statins, ezetimibe with or without statins and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors remain unassessed. Design Bayesian network meta-analysis was conducted to compare treatment groups. Methods Thirty-nine randomized controlled trials were selected using MEDLINE, EMBASE, and CENTRAL (inception - September 2017). Results In network meta-analysis of 189,116 patients, PCSK9 inhibitors were ranked as the best treatment for prevention of major adverse cardiovascular events (Surface Under Cumulative Ranking Curve (SUCRA), 85%), myocardial infarction (SUCRA, 84%) and stroke (SUCRA, 80%)...
January 1, 2018: European Journal of Preventive Cardiology